Wearable Epileptic Seizure Prediction and Alert Glasses Based on Neuromorphic Computing

Wearable Epileptic Seizure Prediction and Alert Glasses Based on Neuromorphic Computing

The NEXA study aims to evaluate a new wearable EEG device designed as smart glasses with dry electrodes positioned according to the 10-20 system. The device captures real-time brain signals to detect patterns that may predict seizures, helping people with epilepsy. This study will test the device's safety, performance, and usability before seeking regulatory approval, including FDA clearance. The NEXA device is investigational and not yet approved by the U.S. FDA. The study will involve human participants who will wear the device while data is collected and analyzed. Results will help improve the device and support future certification for medical use.

The NEXA Study is a prospective observational clinical trial designed to evaluate the safety, comfort, and performance of the NEXA wearable EEG device in patients with epilepsy. NEXA uses an innovative dry electrode system (two dome-shaped electrodes at the front and two spiked electrodes above the ears) aligned with the 10-20 EEG placement system to capture high-quality brain signals without the need for gels. The device integrates real-time artifact removal algorithms and a low-power neuromorphic chip for seizure detection and prediction. The study will compare NEXA's performance against standard EEG monitoring in hospital settings across Oman, with the primary goal of determining its accuracy in seizure detection and prediction. Secondary outcomes include electrode comfort, usability, compliance, and safety. Data from this study will support regulatory submissions and demonstrate NEXA's potential as a practical and reliable solution for continuous EEG monitoring.

Inclusion Criteria:

• Adults (≥18 years) with a confirmed epilepsy diagnosis by a neurologist or epilepsy specialist.
• History of active seizures within the last year, under stable treatment (medications, VNS, diet, or surgery) for at least 3 months.
• Capacity to provide informed consent (or via legal representative if cognitively impaired).
• Willingness to participate and sign consent.
• Residents of Oman attending Khoula Hospital or affiliated clinics.
• Stable general health without acute or severe comorbidities.
• Ability and willingness to attend study visits and follow protocols.

Exclusion Criteria:

• Seizures from non-epileptic causes (e.g., psychogenic, metabolic, tumors).
• Under 18 years of age.
• Severe cognitive impairment preventing consent or protocol adherence.
• Pregnant or planning pregnancy during the study.
• Severe uncontrolled medical conditions (e.g., heart disease, cancer).
• History of non-compliance with epilepsy treatment or follow-ups.
• Severe psychiatric disorders affecting participation or safety.
• History of substance abuse interfering with study adherence.
• Known allergies or hypersensitivity to study medications or procedures.